Graves’ Disease Plasma
Graves' Disease Plasma - Cryopreserved human plasma from clinically confirmed Graves' disease donors. Ideal for TSH receptor stimulating autoantibody (TRAb, TSI, TBII) work, thyroid hormone measurement, cytokine analysis, and thyroid eye disease biomarker discovery.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73325 | Graves' Disease | 1.0 ML | Hispanic/Latino | 38 | Female | United States |
levothyroxine 125mcg QD
|
15 | $495.00 | |
| 71781 | Graves' Disease | 1.0 ML | Asian/Pacific Islander | 38 | Male | United States |
Methimazole 5mg QD; QVAR 80mcg/2xday; Propranolol 10mg QD
|
9 | $495.00 | |
| 70526 | Graves' Disease | 1.0 ML | Native American | 63 | Male | United States | 16 | $495.00 | ||
| 69442 | Graves' Disease | 1.0 ML | Caucasian | 44 | Female | United States |
Methimazole 10mg daily, other supplements Methimazole, 5mg, QD Iron, 65mg QD Vitamin D3, 5000 U, QD Pro-Air, PID Vitamin B-12, QD Albuterol Inh PRN busparone 10mg QD
|
14 | $495.00 | |
| 69353 | Graves' Disease | 1.0 ML | African American | 60 | Female | United States |
Vitamins, C, E, D, biotin, selenium, velafaxine 150mg and 75mg, Meloxicam, methamazol, metoprolol, atorvastatin, buspar Adorvastin Venlofaxin Metropolol
|
16 | $495.00 | |
| 69291 | Graves' Disease | 1.0 ML | Asian/Pacific Islander | 66 | Male | United States |
No medications
|
8 | $495.00 | |
| 69460 | Graves' Disease | 1.0 ML | Asian/Pacific Islander | 26 | Female | United States |
methamisol 2.25 mg 5 days a week
|
16 | $495.00 | |
| 69382 | Graves' Disease | 1.0 ML | Caucasian | 63 | Female | United States |
Levothyroxine, liothyronine. Temazapam Levothyroxine 88 mcg QD Liothyronine 5 mcg QD Hizentra 12gm/60 ml Infusion QD
|
16 | $495.00 | |
| 68848 | Graves' Disease | 1.0 ML | Native American | 63 | Male | United States | 14 | $495.00 |
Graves’ Disease Plasma for Autoimmune Thyroid Disease Research
Graves’ Disease Plasma is collected from IRB-consented donors clinically diagnosed with Graves’ disease and processed within one day of collection to preserve autoantibodies, hormones, cytokines, proteins, and metabolites. Graves’ disease is an autoimmune thyroid disorder caused by stimulating autoantibodies against the thyrotropin (TSH) receptor, which mimic TSH, drive unregulated thyroid hormone production, and cause hyperthyroidism with diffuse goitre. Plasma is acellular and is intended for soluble-analyte measurement rather than cell-based assays.
Disease Biology and Why Plasma
- TSH receptor autoantibodies (TRAb) are the direct cause of disease. Unusually among autoimmune conditions, the pathogenic antibody is stimulating rather than blocking or destructive, making Graves’ a reference model for agonist autoantibody biology.
- Functional assay substrate: thyroid-stimulating immunoglobulin (TSI) bioassays and TSH-binding inhibitory immunoglobulin (TBII) assays both use circulating antibody and require acellular donor material.
- Additional thyroid autoantibodies — anti-thyroid peroxidase (TPO) and anti-thyroglobulin — are frequently present and useful for distinguishing and overlapping with Hashimoto’s thyroiditis.
- Thyroid function analytes: TSH, free T4 and free T3 can be measured from the same aliquot, allowing antibody titre to be related to hormonal status.
- Thyroid eye disease: a substantial subset of donors develop orbitopathy driven by TSH receptor and IGF-1 receptor signalling in orbital fibroblasts, the target of newer biologic therapy.
- Cytokine and immune profiling supports work on the Th1/Th2/Th17 balance and B-cell help underpinning autoantibody production.
Donor Stratification Available
- TSH receptor antibody status and titre where available
- Additional autoantibody positivity: anti-TPO, anti-thyroglobulin
- Biochemical status at collection: overt hyperthyroid, subclinical, or euthyroid on treatment
- Presence and activity of thyroid eye disease / Graves’ orbitopathy
- Treatment status: antithyroid drugs (methimazole, propylthiouracil), radioiodine therapy, post-thyroidectomy, biologic therapy for orbitopathy, or treatment-naive
- Coexisting autoimmune conditions such as type 1 diabetes, vitiligo, or coeliac disease
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed Graves’ disease donors
- Processed within one day of collection
- Anticoagulant selection available on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified Graves’ disease diagnosis
- Thyroid function and autoantibody results where available
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Additional Graves’ disease-specific metadata available
Applications
- TSH receptor autoantibody detection, titration, and stimulating versus blocking characterisation
- TSI bioassay and TBII assay development and validation
- Anti-TPO and anti-thyroglobulin autoantibody profiling
- Thyroid hormone and TSH immunoassay development
- Thyroid eye disease biomarker research, including IGF-1 receptor pathway work
- Cytokine and inflammation profiling
- Proteomic and metabolomic biomarker discovery
- Therapeutic response and relapse-prediction research
Other Graves’ Disease Specimen Types
Graves’ disease donor material is also available as Graves’ Disease Serum, Graves’ Disease PBMC, Graves’ Disease Whole Blood, Graves’ Disease Leukopak, and Graves’ Disease Bulk Plasma. Related cohorts include Thyroid Eye Disease Plasma and Hyperthyroidism Serum.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Graves’ disease plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For the full specimen range, see our human plasma collection.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.